Related content

Tackling EGFR signaling with TACE antagonists: a rational target for metalloprotease inhibitors in cancer

By Kenny Paraic A  

Expert Opinion on Therapeutic Targets, Vol. 11, Iss. 10, 2007-10 ,pp. : 1287-1298

Informa Healthcare

Access to resources Recommend Favorite

Critical Roles of EGFR Family Members in Breast Cancer and Breast Cancer Stem Cells: Targets for Therapy

By  

Current Pharmaceutical Design, Vol. 22, Iss. 16, 2016-05 ,pp. : 2358-2388

Bentham Science Publishers

Access to resources Recommend Favorite

Emerging drugs in metastatic breast cancer: an update

By Arslan Cagatay   Altundag Kadri   Dizdar Omer  

Expert Opinion on Emerging Drugs, Vol. 16, Iss. 4, 2011-12 ,pp. : 647-667

Informa Healthcare

Access to resources Recommend Favorite

Steroidal and nonsteroidal oestrogen antagonists in breast cancer: basic and clinical appraisal

By Favoni R.E.   de Cupis A.  

Trends in Pharmacological Sciences, Vol. 19, Iss. 10, 1998-10 ,pp. : 406-415

Elsevier

Access to resources Recommend Favorite

Measurements of EGFR expression on circulating tumor cells are reproducible over time in metastatic breast cancer patients

By Payne Rachel E   Yagüüe Ernesto   Slade Martin J   Apostolopoulos Christos   Jiao Long R   Ward Becky   Coombes R Charles   Stebbing Justin  

Pharmacogenomics, Vol. 10, Iss. 1, 2009-01 ,pp. : 51-57

Future Medicine

Access to resources Recommend Favorite